Trilaciclib: Experimental Treatment for Small-Cell Lung Cancer (SCLC)

Scientific rationale and therapeutic potential

Trilaciclib is a short-acting CDK4/6 inhibitor given as a 30-minute IV infusion prior to chemotherapy. Trilaciclib is designed to:

Clinical results

Trilaciclib’s potential in SCLC has been encouraging to date (see: Publications):

G1 is currently conducting three Phase 2 trials in SCLC

G1T28-02 Study G1T28-03 Study G1T28-05 Study
  • First-line extensive stage SCLC
  • Multi-center, randomized, placebo-controlled
  • Carboplatin and etoposide + trilaciclib
  • Approximately 90 patients
  • ClinicalTrials.gov Identifier: NCT02499770
  • Previously treated SCLC
  • Multi-center, randomized, placebo-controlled
  • Topotecan + trilaciclib
  • Approximately 90 patients
  • ClinicalTrials.gov Identifier: NCT02514447
  • First-line extensive stage SCLC
  • Multi-center, randomized, placebo-controlled
  • Carboplatin/etoposide + atezolizumab + trilaciclib
  • Approximately 100 patients
  • ClinicalTrials.gov Identifier: NCT03041311

For additional information on the trials, please visit: G1CancerTrials.com

Click here for printable version of our trilaciclib SCLC clinical trials fact sheet